The American Society of Clinical Oncology meeting, the world's biggest cancer conference, has kicked off in blazing sunshine and amid much anticipation in Chicago.
AbbVie/Roche's Venclexta (venetoclax) has produced a high overall response rate in chronic lymphocytic leukaemia patients with the 17p deletion mutation, a sub-group who do not respond well
